Abstracts tagged "Biologic agents"

Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Limin Shang¹, Greg Elson¹, Jeremy Sokolove², Iain B. McInnes³, James Reilly⁴, Eric Hatterer¹, Marie Kosco-Vilbois⁵, Walter Ferlin⁵, Emmanuel Monnet⁵ and Cristina de Min⁶, ¹NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵NovImmune S.A., Geneva, Switzerland, ⁶Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Francisco Ortiz-Sanjuan¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, Agustí Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, E. Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, AJ García González³⁸, Raquel Almodovar³⁹, E Minguez⁴⁰, C Carrasco Cubero⁴¹, Alejandro Olive Marques⁴², J Vázquez⁴³, O Ruiz Moreno⁴⁴, F Jimenez-Zorzo⁴⁴, J Manero⁴⁴, Javier Loricera¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴⁰Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴¹Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴²Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴³Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁴Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Masahiro Tada¹, Tatsuya Koike², Akihiro Tamori³, Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Alain Saraux¹, Stephanie Rouanet², Rene-Marc Flipo³, Jean-Cyril Poncet⁴, Patrice Fardellone⁵, Pascal Hilliquin⁶, Isabelle Idier⁷ and Alain G. Cantagrel⁸, ¹Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, ²Medical Department, Roche, Boulogne-Billancourt, France, ³Rheumatology, University Hospital Lille, Lille, France, ⁴Rheumatology, General Hospital Gap, Gap, France, ⁵Service de Rhumatologie, Hôpital Nord, C.H.U. d'Amiens, Amiens, France, ⁶Rheumatology, General Hospital Corbeil, Corbeil-Essonnes, France, ⁷Chugai Pharma, La Defense, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…
Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Gerd Burmester¹, Tsutomu Takeuchi², Olga Barbarash³, Duncan Porter⁴, Didier Saurigny⁵, David Close⁵, Alex Godwood⁵, Yoojung Yang⁶ and Ancilla W. Fernandes⁶, ¹Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁴Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁵MedImmune, Ltd, Cambridge, United Kingdom, ⁶MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…
Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Glenn Haugeberg¹, Torhild Garen², Hege Sommerseth³, Anne Prøven³ and Knut Helgetveit³, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Rheumatology, Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
Abstract Number: 335 • 2013 ACR/ARHP Annual Meeting
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Sabrina Hoa¹, Denis Choquette², Louis Bessette³, Diane Sauvageau⁴, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld⁴, Edith Villeneuve⁴ and Louis Coupal², ¹Rheumatology, Centre hospitalier de l'université de Montréal (Hôpital Notre-Dame), Montréal, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: No long term head-to-head comparative studies of anti-TNF agents in psoriatic arthritis have been published. Controversy exists over the selection of initial biologic therapy…
Abstract Number: 2388 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)
Thao Pham¹, Jacques Morel², Toni Alfaiate³, Emmanuelle Dernis⁴, Philippe Gaudin⁵, Olivier Brocq⁶, Elisabeth Solau-Gervais⁷, Jean-Marie Berthelot⁸, Jean-Charles Balblanc⁹, Xavier Mariette¹⁰, Florence Tubach¹¹ and Bruno Fautrel¹², ¹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁴Le Mans Hospital, Le Mans, France, ⁵Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁶Hospital of Princesse Grâce de Monaco, Monaco, France, ⁷Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁸Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹INSERM, Universite Paris Diderot, Paris, France, ¹²Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The STRASS trial was a 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
Gerd Burmester¹, Patrick Durez², Galina Shestakova³, Yue Li⁴, Amanda Wang⁵, Steve Lewitzky⁵, Irina Koroleva⁵, David Lee⁶ and Wolfgang Hueber⁷, ¹Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Université Catholique de Louvain, Brussels, Belgium, ³Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, ⁴IIS, Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Cambridge, MA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting
Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry
Lene Dreyer¹, Lene Mellemkjær², Inger Marie Jensen Hansen³ and Merete Lund Hetland⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Sarah Ringold¹, Pamela F. Weiss², Robert A. Colbert³, Esi Morgan DeWitt⁴, Tzielan C. Lee⁵, Karen Onel⁶, Sampath Prahalad⁷, Rayfel Schneider⁸, Susan Shenoi⁹, Richard K. Vehe¹⁰ and Yukiko Kimura¹¹, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³NIAMS NIH, Bethesda, MD, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁷Pediatrics, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁹Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, ¹⁰Department of Pediatrics, University of Minnesota, Minneapolis, MN, ¹¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…
Abstract Number: 2367 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Luis Rodriguez-Rodriguez¹, Leticia Leon², Zulema Rosales², Cristina Lajas², Lucía Arietti², Ana B. Rodríguez-Cambrón², Cristina Martínez-Prada², Jose María Leal², Pilar Macarrón², Gloria Candelas², Juan A. Jover² and Lydia Abásolo², ¹Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…
Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Glenn Haugeberg¹, Andreas P. Diamantopoulos¹, Agnete Gulati², Mari Hoff³ and Arthur Kavanaugh⁴, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St.Olavs Hospital, Trondheim, Norway, ³Rheumatology, St Olavs Hospital, Trondheim, Norway, ⁴University of California San Diego, San Diego, CA
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
Abstract Number: 1051 • 2013 ACR/ARHP Annual Meeting
Sociodemographic, Health System, and Community Characteristics Associated With Initiation Of Biological Dmards In RA
Edward H. Yelin¹, Chris Tonner², Seoyoung C. Kim³, Jeffrey N. Katz⁴, John Z. Ayanian⁵ and Daniel H. Solomon⁶, ¹Medicine, UC San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: The use of biologic DMARDs for RA has improved outcomes, but it is unknown whether there are disparities in initiation of these agents by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].